TOP > Publication



  1. Murata T, Yamaguchi M, Kohno S, Takahashi C, Watanabe R, Hatori K, Hikita K, Kaneda N.Regucalcin enhances adipocyte differentiation and attenuates inflammation in 3T3-L1 cells. FEBS Open Bio., July 21 2020. (in press)
  2. Seliverstov RY, Zaraiskiy MI, Tyurin RV, Naryshkin AG, Valerko VG, Semiglazov VV, Takahashi C. MicroRNA in monitoring of the evolution of glial cerebral tumors. Siberian Journal of Oncology, 19:47-53, 2020.
  3. Kohno S*, Linn P*, Nagatani N, Watanabe Y, Kumar S, Soga T and Takahashi C. Pharmacologically targetable vulnerability in prostate cancer carrying RB1-SUCLA2 deletion. , Oncogene, July 21, 2020. (online) *; equally contributed.
  4. Kulathunga N, Kohno S, Linn P, Nishimoto Y, Horike S, Zaraiskii M, Kumar S, Muranaka H, Takahashi C. Peripubertal High Fat Diet Promotes c-Myc Stabilization in Mammary Gland Epithelium. Cancer Sci. May 21, 2020. (in press).
  5. Thumkeo D, Katsura Y, Nishimura Y,Kanchanawong P,Tohyama K, Ishizaki T, Kitajima S, Takahashi C,Hirata T,Watanabe N,Krummel MF and Narumiya S.mDia1/3-dependent actin polymerization spatiotemporally controls LAT phosphorylation by Zap70 at the immune synapse. Science Advances 2020 Jan 1;6(1):e2432.
  6. Li F*, Kitajima S*, Kohno S, Yoshida A, Tange S, Sasaki S, Okada N, Nishimoto Y, Muranaka H, Nagatani N, Suzuki M, Masuda S, Thai TC, Nishiuchi T, Tanaka T, Barbie DA, Mukaida N and Takahashi C. RB inactivation induces a protumoral microenvironment via enhanced CCL2 secretion. Cancer Research, 79:3903-3915, 2019. doi: 10.1158/0008-5472.CAN-18-3604. * equal contribution.
    Link 1】 【Link 2】 【Link 3
  7. Nishimura T, NakataA, Xiaoxi C, Nishi K, Meguro-Horike M, Sasaki S,Kita K, Horike S,Saitoh K, Kato K, Kaori I, Murayama T, Kohno S, Takahashi C, Mukaida M, Yano S, Soga T, Tojo A and Gotoh N. Cancer stem-like properties and gefitinib resistance are dependent on purine synthetic metabolism mediated by the mitochondrial enzyme MTHFD2. Oncogene, 38:2464-2481, 2019.
  8. Kitajima S, Asahina H, Chen T, Guo S, Laura GQ, Cavanaugh JD, Merlino AA, Tange S, Terai H, Kim JW, Wang X, Zhou S, Xu N, Wang S, Zhu Z, Thai TC, Takahashi C, Wang Y, Neve R, Stinson S, Tamayo P, Watanabe H, Kirschmeier PT, K Wong KK, and Barbie DA. Overcoming resistance to dual innate immune and MEK inhibition downstream of KRAS. Cancer Cell 34:439-452, 2018.
  9. Zhao J, Okamoto Y, Asano Y, Ishimaru K, Aki S, Yoshioka K, Takuwa N, Wada T, Inagaki Y, Takahashi C, Nishiuchi T, Takuwa Y. Sphingosine-1-phosphate receptor-2 facilitates pulmonary fibrosis through potentiating IL-13 pathway in macrophages. PLoS One, 13(5):e0197604, 2018.
  10. Sasaki S, Baba T, Muranaka H, TanabeY, Takahashi C, Matsugo S and Mukaida N. Involvement of prokineticin 2-expressing neutrophil infiltration in 5-fluorouracil-induced aggravation of breast cancer metastasis to lung. Mol Cancer Ther, 17:1515-1525, 2018.
  11. Murata T, Yamaguchi Y, Kohno S, Takahashi C, Kakimoto M, Sugimura Y, Kamihara M, Hikita K and Kaneda N. Regucalcin confers resistance to amyloid-β toxicity in neuronally differentiated PC12 cells. FEBS openbio, 8:349-360, 2018.
  12. Muranaka H, Hayashi A, Minami K, Kitajima S, Kohno S, Nishimoto Y, Nagatani N, Suzuki M, Kulathunga N, Sasaki N, Okada N, Matsuzaka T, Shimano H, Tada H and Takahashi C. A distinct function of the retinoblastoma protein in the control of lipid composition identified by lipidomic profiling. Oncogenesis 26;6 (6):e350, 2017.
  13. Kitajima S, Yoshida A, Kohno S, Li F, Suzuki S, Nagatani N, Nishimoto Y, Sasaki N, Muranaka H, Wan Y, Thai T C, Okahashi N, Matsuda F, Shimizu H, Nishiuchi T, Suzuki Y, Tominaga K, Gotoh N, Suzuki M, Ewen M E, Barbie D A, Hirose O, Tanaka T and Takahashi C.The RB-IL-6 axis controls self-renewal and endocrine therapy resistance by fine-tuning mitochondrial activity. Oncogene 36:5145-5157, 2017.
  14. Nagata N, Xu L, Kohno S, Ushida Y, Aoki Y, Umeda R, Fuke N, Zhuge F, Ni Y, Nagashimada M, Takahashi C, Suganuma H, Kaneko S and Ota T. Glucoraphanin ameliorates obesity and insulin resistance through adipose tissue browning and reduction of metabolic endotoxemia in mice. Diabetes 66:1222-1236, 2017.
  15. Yoshida A, Kitajima S, Li F, Chaoyang C, Yujiro T, Kohno S, Wan Y, Hayashi N, Muranaka H, Nishimoto Y, Nagatani N, Nishiuchi T, Thai T C, Suzuki S, Nakao S, Tanaka T, Hirose O, Barbie D A and Takahashi C. MicroRNA-140 mediates RB tumor suppressor function to control stem cell-like activity through interleukin-6. Oncotarget 8:13872-13885, 2017.
  16. Hegazy AM, Yamada D, Kobayashi M, Kohno S, Ueno M, Ali MA, Ohta K, Tadokoro Y, Ino Y, Todo T, Soga T, Takahashi C and Hirao A. Therapeutic strategy for targeting aggressive malignant gliomas by disrupting their energy balance. J Bio Chem, 291:21496-21509, 2016.
  17. Kitajima S, Li F, Takahashi C. Primary Culture of Mouse Thyroid Calcitonin-producing Cell (C cell) Tumors. Bio-Protocol, 5, 2015. (http://bio-protocol.org/e1681)
  18. Salah M, Nishimoto Y, Kohno S, Kondoh A, Kitajima S, Muranaka H, Nishiuchi T, Ibrahim A, Yoshida A and Takahashi C. An in vitro system to characterize prostate cancer progression identified signaling required for self-renewal. Mol Carcinog, 55:1974-1989, 2016.
  19. Gutiérrez J, Droppelmann CA, Contreras O, Takahashi C, Brandan E. RECK-mediated β1-integrin regulation by TGF-β1 is critical for wound contraction in mice. PLoS One,10(8):e0135005, 2015.
  20. Okahashi N, Kohno S, Kitajima S, Matsuda F, Takahashi C, Shimizu H.Metabolic characterization of cultured mammalian cells by mass balance analysis, tracer labeling experiments and computer-aided simulations. J Biosci Bioeng, 120:725-731, 2015.
  21. Kitajima S*, Kohno S*, Kondoh A, Sasaki N. Nishimoto Y, Li F, Mohammed SA, Muranaka H, Nagatani N, Suzuki M, Kido Y and Takahashi C. Undifferentiated state induced by Rb-p53 double inactivation in mouse thyroid neuroendocrine cells and embryonic fibroblasts. Stem Cells, 33: 1657-1669, 2015. *; equally contributed.
  22. Rajabi HN, Takahashi C and Ewen ME. Retinoblastoma protein and MyoD function together to effect the repression of Fra-1 and in turn Cyclin D1 during terminal cell cycle arrest associated with myogenesis. J Biol Chem 289: 23417-23427, 2014.
  23. Ali MA, Naka K, Yoshida A, Fuse K, Kasada A, Hoshii T, Tadokoro Y, Ueno M, Ohta K, Kobayashi M, Takahashi C, Hirao A. Association of a murine leukaemia stem cell gene signature based on nucleostemin promoter activity with prognosis of acute myeloid leukaemia in patients. Biochem Biophys Res Commun, 450: 837-843, 2014.
  24. Siddesha JM, Valente AJ, Sakamuri SS, Yoshida T, Gardner JD, Somanna N, Takahashi C, Noda M, Chandrasekar B. Angiotensin II stimulates cardiac fibroblast migration via the differential regulation of matrixins and RECK. J Mol Cell Cardiol 65: 9-18, 2013. 
  25. Hayashi N, Kobayashi M, Shamma A, Morimura Y, Takahashi C, Yamamoto KI. Regulatory interaction between NBS1 and DNMT1 responding to DNA damage. J Biochem, 154: 429-435, 2013.
  26. Shamma A, Suzuki M, Hayashi, N, Kobayashi M, Sasaki N, Nishiuchi T, Doki Y, Okamoto T, Kohno S, Muranaka H, Kitajima S, Yamamoto K, Takahashi C. ATM mediates pRB function to control DNMT1 protein stability and DNA methylation. Mol Cell Biol, 33: 3113-3124, 2013.
  27. Taura M, Suico M A, Koyama K, Komatsu K, Miyakita R, Matsumoto C, Kudo E, Kariya R, Goto H, Kitajima S, Takahashi C, Shuto T, Nakao M, Okada S, and Kai H. Rb/E2F1 regulates the innate immune receptor Toll-like receptor 3 in epithelial cells. Mol Cell Biol,32: 1581-1590, 2012.
  28. Kitajima S, Miki T, Takegami Y, Kido Y, Noda M, Hara E, Shamma A, and Takahashi C. Reversion-inducing cysteine-rich protein with Kazal motifs interferes with epidermal growth factor receptor signaling. Oncogene,30: 737-750, 2011.
  29. Chandana E P, Maeda Y, Ueda A, Kiyonari H, Oshima N, Yamamoto M, Kondo S, Oh J, Takahashi R, Yoshida Y, Kawashima S, Alexander D B, Kitayama H, Takahashi C, Tabata Y, Matsuzaki T, and Noda M. Involvement of the Reck tumor suppressor protein in maternal and embryonic vascular remodeling in mice. BMC Dev Biol,10: 84-96, 2010.
  30. Loayza-Puch F, Yoshida Y, Matsuzaki T, Takahashi C, Kitayama H, and Noda M. Hypoxia and RAS-signaling pathways converge on, and cooperatively downregulate, the RECK tumor-suppressor protein through microRNAs. Oncogene,29: 2638-2648, 2010.
  31. Miki T, Shamma A, Kitajima S, Takegami Y, Noda M, Nakashima Y, Watanabe K, and Takahashi C. The β1-integrin-dependent function of RECK in physiologic and tumor angiogenesis. Mol Cancer Res,8: 665-676, 2010.
  32. Omura A, Matsuzaki T, Mio K, Ogura T, Yamamoto M, Fujita A, Okawa K, Kitayama H, Takahashi C, Sato C, and Noda M. RECK forms cowbell-shaped dimers and inhibits matrix metalloproteinase-catalyzed cleavage of fibronectin. J Biol Chem,284: 3461-3469, 2009.
  33. Shamma A, Takegami Y, Miki T, Kitajima S, Noda M, Obara T, Okamoto T, and Takahashi C. Rb Regulates DNA damage response and cellular senescence through E2F-dependent suppression of N-ras isoprenylation. Cancer Cell,15: 255-269, 2009.
  34. Kawashima S, Imamura Y, Chandana E P, Noda T, Takahashi R, Adachi E, Takahashi C, and Noda M. Localization of the membrane-anchored MMP-regulator RECK at the neuromuscular junctions. J Neurochem,104: 376-385, 2008.
  35. Fotiadou P P, Takahashi C, Rajabi H N, and Ewen M E. Wild-type NRas and KRas perform distinct functions during transformation. Mol Cell Biol,27: 6742-6755, 2007.
  36. Miki T, Takegami Y, Okawa K, Muraguchi T, Noda M, and Takahashi C. The reversion-inducing cysteine-rich protein with Kazal motifs (RECK) interacts with membrane type 1 matrix metalloproteinase and CD13/aminopeptidase N and modulates their endocytic pathways. J Biol Chem,282: 12341-12352, 2007.
  37. Muraguchi T, Takegami Y, Ohtsuka T, Kitajima S, Chandana E P, Omura A, Miki T, Takahashi R, Matsumoto N, Ludwig A, Noda M, and Takahashi C. RECK modulates Notch signaling during cortical neurogenesis by regulating ADAM10 activity. Nat Neurosci,10: 838-845, 2007.
  38. Nakaji K, Ihara M, Takahashi C, Itohara S, Noda M, Takahashi R, and Tomimoto H. Matrix metalloproteinase-2 plays a critical role in the pathogenesis of white matter lesions after chronic cerebral hypoperfusion in rodents. Stroke,37: 2816-2823, 2006.
  39. Takahashi C, Contreras B, Iwanaga T, Takegami Y, Bakker A, Bronson R T, Noda M, Loda M, Hunt J L, and Ewen M E. Nras loss induces metastatic conversion of Rb1-deficient neuroendocrine thyroid tumor. Nat Genet,38: 118-123, 2006.
  40. Echizenya M, Kondo S, Takahashi R, Oh J, Kawashima S, Kitayama H, Takahashi C, and Noda M. The membrane-anchored MMP-regulator RECK is a target of myogenic regulatory factors. Oncogene,24: 5850-5857, 2005.
  41. Ihara M, Kinoshita A, Yamada S, Tanaka H, Tanigaki A, Kitano A, Goto M, Okubo K, Nishiyama H, Ogawa O, Takahashi C, Itohara S, Nishimune Y, Noda M, and Kinoshita M. Cortical organization by the septin cytoskeleton is essential for structural and mechanical integrity of mammalian spermatozoa. Dev Cell,8: 343-352, 2005.
  42. Takenaka K, Ishikawa S, Yanagihara K, Miyahara R, Hasegawa S, Otake Y, Morioka Y, Takahashi C, Noda M, Ito H, Wada H, and Tanaka F. Prognostic significance of reversion-inducing cysteine-rich protein with Kazal motifs expression in resected pathologic stage IIIA N2 non-small-cell lung cancer. Ann Surg Oncol,12: 817-824, 2005.
  43. Oh J, Seo D W, Diaz T, Wei B, Ward Y, Ray J M, Morioka Y, Shi S, Kitayama H, Takahashi C, Noda M, and Stetler-Stevenson W G. Tissue inhibitors of metalloproteinase 2 inhibits endothelial cell migration through increased expression of RECK. Cancer Res,64: 9062-9069, 2004.
  44. Oh J, Takahashi R, Adachi E, Kondo S, Kuratomi S, Noma A, Alexander D B, Motoda H, Okada A, Seiki M, Itoh T, Itohara S, Takahashi C, and Noda M. Mutations in two matrix metalloproteinase genes, MMP-2 and MT1-MMP, are synthetic lethal in mice. Oncogene,23: 5041-5048, 2004.
  45. Takahashi C, Contreras B, Bronson R T, Loda M, and Ewen M E. Genetic interaction between Rb and K-ras in the control of differentiation and tumor suppression. Mol Cell Biol,24: 10406-10415, 2004.
  46. Takenaka K, Ishikawa S, Kawano Y, Yanagihara K, Miyahara R, Otake Y, Morioka Y, Takahashi C, Noda M, Wada H, and Tanaka F. Expression of a novel matrix metalloproteinase regulator, RECK, and its clinical significance in resected non-small cell lung cancer. Eur J Cancer,40: 1617-1623, 2004.
  47. Takeuchi T, Hisanaga M, Nagao M, Ikeda N, Fujii H, Koyama F, Mukogawa T, Matsumoto H, Kondo S, Takahashi C, Noda M, and Nakajima Y. The membrane-anchored matrix metalloproteinase (MMP) regulator RECK in combination with MMP-9 serves as an informative prognostic indicator for colorectal cancer. Clin Cancer Res,10: 5572-5579, 2004.
  48. Arai T, Kasper J S, Skaar J R, Ali S H, Takahashi C, and DeCaprio J A. Targeted disruption of p185/Cul7 gene results in abnormal vascular morphogenesis. Proc Natl Acad Sci U S A,100: 9855-9860, 2003.
  49. Takahashi C, Bronson R T, Socolovsky M, Contreras B, Lee K Y, Jacks T, Noda M, Kucherlapati R, and Ewen M E. Rb and N-ras function together to control differentiation in the mouse. Mol Cell Biol,23: 5256-5268, 2003.
  50. Furumoto K, Arii S, Mori A, Furuyama H, Gorrin Rivas M J, Nakao T, Isobe N, Murata T, Takahashi C, Noda M, and Imamura M. RECK gene expression in hepatocellular carcinoma: correlation with invasion-related clinicopathological factors and its clinical significance. Reverse-inducing--cysteine-rich protein with Kazal motifs. Hepatology,33: 189-195, 2001.
  51. Oh J, Takahashi R, Kondo S, Mizoguchi A, Adachi E, Sasahara R M, Nishimura S, Imamura Y, Kitayama H, Alexander D B, Ide C, Horan T P, Arakawa T, Yoshida H, Nishikawa S, Itoh Y, Seiki M, Itohara S, Takahashi C, and Noda M. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell,107: 789-800, 2001.
  52. Izumi H, Takahashi C, Oh J, and Noda M. Tissue factor pathway inhibitor-2 suppresses the production of active matrix metalloproteinase-2 and is down-regulated in cells harboring activated ras oncogenes. FEBS Lett,481: 31-36, 2000.
  53. Sasahara R M, Takahashi C, and Noda M. Involvement of the Sp1 site in ras-mediated downregulation of the RECK metastasis suppressor gene. Biochem Biophys Res Commun,264: 668-675, 1999.
  54. Ishida-Takahashi A, Otani H, Takahashi C, Washizuka T, Tsuji K, Noda M, Horie M, and Sasayama S. Cystic fibrosis transmembrane conductance regulator mediates sulphonylurea block of the inwardly rectifying K+ channel Kir6.1. J Physiol,508: 23-30, 1998.
  55. Takahashi C, Sheng Z, Horan T P, Kitayama H, Maki M, Hitomi K, Kitaura Y, Takai S, Sasahara R M, Horimoto A, Ikawa Y, Ratzkin B J, Arakawa T, and Noda M. Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proc Natl Acad Sci U S A,95: 13221-13226, 1998.
  56. Takahashi C, Akiyama N, Matsuzaki T, Takai S, Kitayama H, and Noda M. Characterization of a human MSX-2 cDNA and its fragment isolated as a transformation suppressor gene against v-Ki-ras oncogene. Oncogene,12: 2137-2146, 1996.
  57. Takahashi C, Kumagai S, Tsubata R, Sorachi K, Ozaki S, Imura H, and Nakao K. Portal hypertension associated with anticardiolipin antibodies in a case of systemic lupus erythematosus. Lupus,4: 232-235, 1995.
  58. Adachi Y, Copeland T D, Takahashi C, Nosaka T, Ahmed A, Oroszlan S, and Hatanaka M. Phosphorylation of the Rex protein of human T-cell leukemia virus type I. J Biol Chem,267: 21977-21981, 1992.
  59. Adachi Y, Ishida-Takahashi A, Takahashi C, Takano E, Murachi T, and Hatanaka M. Phosphorylation and subcellular distribution of calpastatin in human hematopoietic system cells. J Biol Chem,266: 3968-3972, 1991.
  60. Tanaka A, Takahashi C, Yamaoka S, Nosaka T, Maki M, and Hatanaka M. Oncogenic transformation by the tax gene of human T-cell leukemia virus type I in vitro. Proc Natl Acad Sci U S A,87: 1071-1075, 1990.


  1. Kitajima S, Li F, Takahashi C. Tumor Milieu Controlled by RB Tumor Suppressor. Int J Mol Sci., 2020 Apr1;21(7).
  2. Kitajima S and Takahashi C. The intersection of RB tumor suppressor function, stem cells, metabolism and inflammation. Cancer Science 108(9): 1726-1731, 2017.
  3. Kohno S, Kitajima S, Sasaki N and Takahashi C. RB tumor suppressor functions shared by stem cell and cancer cell strategies. World J Stem Cells, 8: 170-184, 2016.
  4. Hayashi N. and Takahashi C. Pleiotropic functions of RB protein in tumour suppression. Archives in Cancer Res, 2015. (on line)
  5. Takahashi C, Sasaki N, and Kitajima S. Twists in views on RB functions in cellular signaling, metabolism and stem cells. Cancer Sci, 103: 1182-1188, 2012.
  6. Noda M, Takahashi C, Matsuzaki T, and Kitayama H. What we learn from transformation suppressor genes: lessons from RECK. Future Oncol,6: 1105-1116, 2010.
  7. Noda M, and Takahashi C. Recklessness as a hallmark of aggressive cancer. Cancer Sci,98: 1659-1665, 2007.
  8. Takahashi C, and Ewen M E. Genetic interaction between Rb and N-ras: differentiation control and metastasis. Cancer Res,66: 9345-9348, 2006.
  9. Noda M, Oh J, Takahashi R, Kondo S, Kitayama H, and Takahashi C. RECK: a novel suppressor of malignancy linking oncogenic signaling to extracellular matrix remodeling. Cancer Metastasis Rev,22: 167-175, 2003.
  10. Sasahara R M, Brochado S M, Takahashi C, Oh J, Maria-Engler S S, Granjeiro J M, Noda M, and Sogayar M C. Transcriptional control of the RECK metastasis/angiogenesis suppressor gene. Cancer Detect Prev,26: 435-443, 2002.
  11. Sasahara R M, Takahashi C, Sogayar M C, and Noda M. Oncogene-mediated downregulation of RECK, a novel transformation suppressor gene. Braz J Med Biol Res,32: 891-895, 1999.
  12. Takahashi C, Akiyama N, Kitayama H, Takai S, and Noda M. Possible involvement of MSX-2 homeoprotein in v-ras-induced transformation. Leukemia,11 Suppl 3: 340-343, 1997.